176 related articles for article (PubMed ID: 27330726)
1. Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38).
Kanatsuka A; Sato Y; Kawai K; Hirao K; Kobayashi M; Kashiwagi A; ; Abe N; Arai K; Fujiya H; Fukumoto Y; Dake F; Iizumi T; Ito M; Iwasaki K; Kanamori A; Kato S; Kato M; Kawara A; Kimura K; Chikamori K; Iemitsu K; Kou S; Kudo M; Kurihara Y; Lee G; Tsuruoka A; Manda N; Matoba K; Hayashi H; Minami M; Kuribayashi N; Miyazawa K; Chiba Y; Osonoi T; Nakamura S; Sasaki H; Komori K; Oishi M; Okada A; Okuguchi F; Yanagisawa M; Sugimoto H; Sugiyama H; Takai M; Takaki M; Takamura H; Takeda H; Takeda H; Tanaka K; Miwa T; Tomonaga O; Taguchi M; Yamazaki K; Wada T; Yagi N; Yamaoka K; Yuhara A
J Diabetes Investig; 2016 May; 7(3):386-95. PubMed ID: 27330726
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.
Bidulka P; Lugo-Palacios DG; Carroll O; O'Neill S; Adler AI; Basu A; Silverwood RJ; Bartlett JW; Nitsch D; Charlton P; Briggs AH; Smeeth L; Douglas IJ; Khunti K; Grieve R
BMJ; 2024 May; 385():e077097. PubMed ID: 38719492
[TBL] [Abstract][Full Text] [Related]
3. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
4. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study.
Lee KA; Jin HY; Kim YJ; Kim SS; Cho EH; Park TS
Medicine (Baltimore); 2022 Feb; 101(8):e28823. PubMed ID: 35212277
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
[TBL] [Abstract][Full Text] [Related]
6. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality.
Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
Diabetes Obes Metab; 2014 Oct; 16(10):977-83. PubMed ID: 24762119
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Lukashevich V; Del Prato S; Araga M; Kothny W
Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
[TBL] [Abstract][Full Text] [Related]
9. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
Montvida O; Shaw JE; Blonde L; Paul SK
Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.
Gitt AK; Bramlage P; Binz C; Krekler M; Deeg E; Tschöpe D
Int J Clin Pract; 2013 Oct; 67(10):1005-14. PubMed ID: 23981060
[TBL] [Abstract][Full Text] [Related]
11. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.
Rathmann W; Kostev K; Gruenberger JB; Dworak M; Bader G; Giani G
Diabetes Obes Metab; 2013 Jan; 15(1):55-61. PubMed ID: 22862879
[TBL] [Abstract][Full Text] [Related]
12. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
Lee SJ; Ha KH; Lee JH; Lee H; Kim DJ; Kim HC
PLoS One; 2019; 14(2):e0211959. PubMed ID: 30742667
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
14. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
Aso Y; Ozeki N; Terasawa T; Naruse R; Hara K; Suetsugu M; Takebayashi K; Shibazaki M; Haruki K; Morita K; Inukai T
Transl Res; 2012 Jan; 159(1):25-31. PubMed ID: 22153807
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice.
Bazo-Alvarez JC; Pal K; Pham TM; Nazareth I; Petersen I; Sharma M
Sci Rep; 2021 Dec; 11(1):23826. PubMed ID: 34903733
[TBL] [Abstract][Full Text] [Related]
16. Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
Fu AZ; Sheehan JJ
Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and satisfaction in patients with type 2 diabetes newly initiating oral monotherapy with antidiabetic drugs in Japan: results from the prospective Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND).
Tajima A; Tobe K; Eiki JI; Origasa H; Watada H; Shimomura I; Tokita S; Kadowaki T
BMJ Open Diabetes Res Care; 2022 Dec; 10(6):. PubMed ID: 36585033
[TBL] [Abstract][Full Text] [Related]
18. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink.
Wilding J; Godec T; Khunti K; Pocock S; Fox R; Smeeth L; Clauson P; Fenici P; Hammar N; Medina J
BMC Med; 2018 Jul; 16(1):116. PubMed ID: 30008267
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment.
Rizzo MR; Barbieri M; Boccardi V; Angellotti E; Marfella R; Paolisso G
J Gerontol A Biol Sci Med Sci; 2014 Sep; 69(9):1122-31. PubMed ID: 24671867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
